Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Hebart

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
International Journal of Cancer|April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Cancer Medicine|June 14, 2021
Preinfection laboratory parameters may predict COVID-19 severity in tumor patientsAlexander Kiani, Romina Roesch, Clemens M Wendtner, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
British Journal of Haematology|September 30, 2017
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trialHermann Einsele, Monika Engelhardt, Christoph Tapprich, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Vaccines|November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple MyelomaKhalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Leukemia|August 30, 2019
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.
Cancers|April 3, 2021
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMMFriederike Bachmann, Martin Schreder, Monika Engelhardt, et al.
Haematologica|September 24, 2016
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trialChristian Straka, Peter Liebisch, Hans Salwender, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
International Journal of Cancer|April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Cancer Medicine|June 14, 2021
Preinfection laboratory parameters may predict COVID-19 severity in tumor patientsAlexander Kiani, Romina Roesch, Clemens M Wendtner, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
British Journal of Haematology|September 30, 2017
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trialHermann Einsele, Monika Engelhardt, Christoph Tapprich, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Vaccines|November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple MyelomaKhalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Leukemia|August 30, 2019
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.
Cancers|April 3, 2021
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMMFriederike Bachmann, Martin Schreder, Monika Engelhardt, et al.
Haematologica|September 24, 2016
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trialChristian Straka, Peter Liebisch, Hans Salwender, et al.
Pageof 7